Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-303/InterAACT 2: Retifanlimab plus carboplatin-paclitaxel in inoperable locally recurrent or metastatic anal canal squamous cell carcinoma
jRCT2031200380Phase 3Completed
- Sponsor
- Incyte
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in anal squamous cell carcinoma (SCCA) comparing Group A: carboplatin + paclitaxel + placebo with Group B: carboplatin + paclitaxel + retifanlimab (2 arms). Primary endpoint: Progression-free survival (PFS). Started Apr 2021; status: completed.
02
Drugs
retifanlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on jRCT2031200380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200380.